Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IN8BIO, Inc. INAB

Healthcare Biotechnology
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400,... see more

Recent & Breaking News (NDAQ:INAB)

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

GlobeNewswire April 30, 2024

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

GlobeNewswire April 24, 2024

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

GlobeNewswire April 16, 2024

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

GlobeNewswire April 9, 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire March 14, 2024

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

GlobeNewswire March 5, 2024

IN8bio to Present at Upcoming Investor Conferences

Business Wire February 26, 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

GlobeNewswire February 14, 2024

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

GlobeNewswire January 4, 2024

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

GlobeNewswire December 11, 2023

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

GlobeNewswire December 11, 2023

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

GlobeNewswire December 7, 2023

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

GlobeNewswire December 5, 2023

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

GlobeNewswire November 20, 2023

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

GlobeNewswire November 10, 2023

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewswire November 6, 2023

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewswire November 3, 2023

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 2, 2023

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

GlobeNewswire November 1, 2023